Mergers and acquisitions

Vaccine
#Immunology / Virology & Vaccines #Mergers and acquisitions #Sanofi #Vicebio

Sanofi acquires vaccine biotech Vicebio for $1.6 billion

Vicebio has agreed to be acquired by Sanofi for a total of $1.6 billion, including an upfront payment of $1.15 billion as well as development and regulatory milestones payments of $450 million.  Vicebio was created by Medicxi to develop vaccines for respiratory viruses utilising its proprietary Molecular Clamp technology, discovered… Read More

#Business & Investment #News

Monoclonal antibody
#AbbVie #Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Monoclonal antibodies #Oncology

AbbVie licenses trispecific antibody in billion-dollar contract

IGI Therapeutics, a wholly owned subsidiary of Ichnos Glenmark Innovation, and AbbVie have announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, for oncology and autoimmune diseases.  “Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by… Read More

#Business & Investment #News

chronic obstructive pulmonary disease
#Cardiovascular disease #Chronic obstructive pulmonary disease (COPD) #Merck #Mergers and acquisitions

Merck acquires Verona, expands cardio-pulmonary portfolio

Merck (known as MSD outside of the US and Canada) is to acquire Verona Pharma for a total transaction value of approximately $10 billion.  Through this acquisition Merck will add Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline… Read More

#Business & Investment #News

#AbbVie #Capstan Therapeutics #CAR-T #Cell therapy #In vivo #Mergers and acquisitions

AbbVie acquires in vivo CAR-T technology with Capstan purchase

AbbVie has revealed it will acquire Capstan Therapeutics, a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs.  The acquisition will include CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase I development for the treatment of B… Read More

#Business & Investment #News

Gene editing
#Eli Lilly #Gene editing #Gene therapy #Mergers and acquisitions #Verve Therapeutics

Lilly to acquire gene editing specialists Verve Therapeutics

Eli Lilly and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve.  Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.   Verve's lead programme… Read More

#Business & Investment #News

Human brain
#Mergers and acquisitions #Neuropsychiatric disorders #Neuroscience #Postpartum depression #Sage Therapeutics #Supernus Pharmaceuticals

Supernus acquires Sage to strengthen neuropsychiatry portfolio

Supernus Pharmaceuticals will acquire Sage Therapeutics through a tender offer totalling approximately $795 million.  The transaction will provide Supernus with Zurzuvae (zuranolone) capsules CIV, the only US Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression.  Through a collaboration agreement with Biogen, Supernus… Read More

#Business & Investment #News #Trending News

#Mergers and acquisitions #Oncology #Prostate cancer #Radiopharmaceuticals #RayzeBio

RayzeBio buys prostate cancer radiopharmaceutical for $1.35bn

Philochem and RayzeBio, a subsidiary of Bristol-Myers Squibb, have announced a definitive agreement under which RayzeBio will purchase the exclusive worldwide rights to prostate cancer therapeutic OncoACP3.  OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer.   The… Read More

#Business & Investment #News

#BioNTech #CureVac #Immunotherapy #Mergers and acquisitions #mRNA #Oncology

BioNTech boosts mRNA expertise with CureVac acquisition

Following a definitive Purchase Agreement, BioNTech has announced its intention to acquire all of the shares of fellow German company CureVac.  With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialisation of investigational mRNA-based cancer immunotherapies.  The company’s oncology strategy focuses on two pan-tumour programmes, mRNA-based cancer… Read More

#Business & Investment #News

#Alzheimer's #Mergers and acquisitions #Neurodegenerative disorders #Neurology #Neuroscience #Sanofi

Sanofi expands neurology pipeline with Vigil Neuroscience acquisition

Sanofi has entered into an agreement to acquire Vigil Neuroscience, a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.  The company says this acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances its early-stage pipeline and includes VG-3927, which will be evaluated… Read More

#Business & Investment #News #Trending News

Human liver
#Fibrosis #GSK #Liver disease #Mergers and acquisitions

GSK buys drug with potential to reverse liver fibrosis

GSK has announced plans to acquire efimosfermin, a Phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD).  The acquisition significantly expands GSK’s hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease, offering multiple development options and potential first launch in… Read More

#Business & Investment #News

#Kidney disease #Mergers and acquisitions #microRNAs #Novartis

Novartis acquires investigational microRNA inhibitor

Novartis has entered into an agreement to acquire Regulus Therapeutics, a clinical-stage biopharmaceutical company focused on developing microRNA therapeutics.  Regulus’ lead asset, farabursen, is a next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).  “With limited treatment options currently available for patients suffering from ADPKD,… Read More

#Business & Investment #News

Human antibodies
#Antibodies #Epsilogen #Mergers and acquisitions #Oncology #Therapeutic Antibodies

Acquisition creates leading pan-isotype cancer antibody company

Epsilogen has completed the acquisition of TigaTx, a biotechnology company developing engineered immunoglobulin A (IgA) antibodies.  As a result, US-based TigaTx will become a wholly owned subsidiary of Epsilogen. Dr Sonia Gulati, a Principal at Global BioAccess Fund, has joined the Epsilogen Board of Directors.  Epsilogen CEO Tim Wilson said:… Read More

#Business & Investment #News

#AstraZeneca #Cell therapy #EsoBiotec #Mergers and acquisitions

AstraZeneca acquires in vivo cell therapy developer

EsoBiotec, a biotechnology company developing in vivo cell therapies, is to be acquired by AstraZeneca.  AstraZeneca will make an initial payment of $425m on deal closing, and up to $575m in contingent consideration based on development and regulatory milestones.  The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform is designed to empower… Read More

#Business & Investment #News

Bristol Myers Squibb offices
#Bristol Myers Squibb #CAR-T #Cell therapy #Mergers and acquisitions

BMS buys CAR-T company 2seventy bio

Bristol Myers Squibb (BMS) is to acquire cell therapy developer 2seventy bio for approximately $286 million.  Under the terms of the agreement, BMS will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction.   2seventy bio’s Board… Read More

#Business & Investment #News

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

New DDW Highlights podcast: 4 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a mixed bag of news for gene therapies this week, ranging from… Read More

#News

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

This week in drug discovery (24-28 February) 

News round-up for 23-28 February by DDW Senior Digital Content Editor Diana Spencer. It’s been a mixed bag of news for gene therapies this week, ranging from huge successes in treating sight impairment, cystic fibrosis and hearing loss, to the quick sale of a previously successful gene therapy… Read More

#News